Deliverbio
1 known investors
Deliver Biosciences develops a nanoparticle-based delivery platform to genetically engineer cells inside patients (in vivo) for cell and gene therapies, using programmable targeting to transport payloads such as DNA and mRNA to specific cell types. Its first product targets T-cells to deliver a CAR gene for cancer immunotherapy, with longer-term applications in autoimmune, neurodegenerative, and cardiovascular diseases.
Investors · 1
Frequently asked questions
- What does Deliverbio do?
- Deliver Biosciences develops a nanoparticle-based delivery platform to genetically engineer cells inside patients (in vivo) for cell and gene therapies, using programmable targeting to transport payloads such as DNA and mRNA to specific cell types. Its first product targets T-cells to deliver a CAR gene for cancer immunotherapy, with longer-term applications in autoimmune, neurodegenerative, and cardiovascular diseases.
- Who are Deliverbio's investors?
- Deliverbio's investors include SciFounders.
